Skip to content

Evaluation of the Impact of Chemotherapy on Body Odor in Adolescents and Young Adults in Oncology

ODORAJA:Evaluation of the Impact of Chemotherapy on Body Odor in Adolescents and Young Adults in Oncology

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04899505
Acronym
ODORAJA
Enrollment
27
Registered
2021-05-24
Start date
2021-10-21
Completion date
2025-05-12
Last updated
2025-05-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chemotherapy Effect, Solid Tumor, Adult, Solid Tumor, Childhood

Brief summary

The appearance of unpleasant body odors in adolescent Young adult (aya) wille be evaluated undergoing chemotherapy

Interventions

OTHEREvaluation on appearance of unpleasant body odors

Percentage of patients reporting discomfort with unpleasant body odor that occurred during their treatment. This percentage will be calculated from the response to item Q1 of the patient questionnaire during the fourth course of chemotherapy in the AJA oncology department.

Sponsors

Institut Curie
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
15 Years to 25 Years
Healthy volunteers
No

Inclusion criteria

* Patients aged between 15 and 25 years; * New patients treated at the Curie Institute and hospitalized in the AJA oncology department; * Patient undergoing chemotherapy administered intravenously; * Solid tumors.

Exclusion criteria

* Patient undergoing oral chemotherapy; * Persons deprived of their liberty or under guardianship (including guardianship); * Inability to undergo medical monitoring of the trial for geographical, social or psychological reasons.

Design outcomes

Primary

MeasureTime frameDescription
Incidence of the development of unpleasant body odors in AYA oncology patients8 monthsPercentage of patients reporting discomfort with unpleasant body odor that occurred during their treatment. This percentage will be calculated from the response to item Q1 of the patient questionnaire during the fourth course of chemotherapy in the AJA oncology department

Secondary

MeasureTime frameDescription
Qualification of the smell and the discomfort felt8 monthsAnswers to the investigation intended for patients for the appearance of the smell with different proposals like sweating, urine, breath etc. (Q2), its qualifier with different proposals like desagreable, infective, nauseating, etc…(Q3) and the discomfort observed for themselves or for those around them (Q8)
Quantification of the discomfort and the impact on quality of life8 monthsAnswers to the investigation intended for patients to assess the intensity of the smell with a scale (0= no smell and 10 = strong smell) (Q4), its daily impact with a scale (0=no impact and 10= high impact) (Q7) and solutions that can reduce smell with different proposals like perfume, cream, essential oil (Q9)
Identify possible causes of the appearance of these new body odors8 monthsAnswers to the investigation for patients to assess the link between smell and drug treatment with different proposals like treatment, hospital's food or hospital cleaning product (Q5 and Q6)

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026